^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    7d
    Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Jul 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    CD19 CAR T cells
    16d
    Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    lenalidomide • Blincyto (blinatumomab)
    24d
    NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy (clinicaltrials.gov)
    P1, N=12, Completed, National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting --> Completed | N=18 --> 12
    Trial completion • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    CD19 positive
    |
    Hyleukin-7 (efineptakin alfa)
    29d
    Cell-based potency assay for anti-CD3-anti-CD19 diabody. (PubMed, J Immunol Methods)
    This novel assay met GMP/GLP compliance, allowing a quantifiable and reproducible measure of efficacy, ensuring batch-to-batch consistency, and met safety and effectiveness regulatory requirements. This potency assay may be applicable for testing other CD3-CD19 T cell engagers and suitable for developing other diabody mediated potency assays with appropriate antigens.
    Journal
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    1m
    Multimodal radiomics machine learning model for predicting the prognosis of lung adenocarcinoma bone metastasis and analysis of traditional Chinese medicine usage patterns (ChiCTR2500110817)
    P=N/A, N=150, Recruiting, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Longhua Hospital Affiliated to Shanghai University of Traditional
    New trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    CD19 positive
    1m
    Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies (ChiCTR2500110470)
    P=N/A, N=19, Not yet recruiting, The First Affiliated Hospital of the University of Science and Technology of China; The First Affiliated Hospital of the University of Science and Tec
    New trial
    |
    CD19 positive
    1m
    Efficacy and safety of a universal CAR19 iNKT cells injection in adult patients with relapsed/refractory CD19-positive B-cell hematological malignancies (ChiCTR2500109007)
    P=N/A, N=8, Not yet recruiting, Nanfang Hospital Ganzhou Hospital (Ganzhou People's Hospital); Ganzhou People's Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    CD19 positive
    2ms
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Sep 2037 | Trial primary completion date: Dec 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    2ms
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (clinicaltrials.gov)
    P1/2, N=17, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=54 --> 17 | Trial completion date: Apr 2041 --> Aug 2040 | Trial primary completion date: Apr 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • iC9-CAR19 cells • rimiducid (AP1903)
    2ms
    Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report. (PubMed, Int J Mol Sci)
    We report a case of a 29-year-old woman with refractory stage IV-B THRLBCL treated with anti-CD19 CAR T-cell therapy (varnimcabtagene autoleucel), who achieved an initial response (day +28) but experienced disease progression by day +100 despite robust CAR T-cell expansion. The patient remains in sustained remission, with persistent B-cell aplasia, four years post-intervention. This case provides clinical and pathological evidence supporting the use of immune checkpoint blockade to rescue CAR T-cell efficacy, highlighting the potential of this synergistic approach in THRLBCL and possibly other B-cell malignancies exhibiting similar immune evasion.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 overexpression • CD19 positive
    |
    Opdivo (nivolumab) • Qartemi (varnimcabtagene autoleucel)
    2ms
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    2ms
    IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=140, Recruiting, Iksuda Therapeutics Ltd. | Trial completion date: Sep 2027 --> Sep 2028 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    IKS03